Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
18 May 2022
18 May 2022
Historique:
entrez:
25
5
2022
pubmed:
26
5
2022
medline:
26
5
2022
Statut:
epublish
Résumé
We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing was performed and compared with parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance nor absence of neutralizing immunity were likely causes of the recrudescence.
Identifiants
pubmed: 35611335
doi: 10.21203/rs.3.rs-1662783/v1
pmc: PMC9128786
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : K08 AI130381
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI131385
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA055491
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054